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Abstract 
The relaxivity displayed by Gd3+ chelates immobilized onto gold nanoparticles is 
the result of complex interplay between nanoparticle size, water exchange rate and 
chelate structure. In this work we study the effect of the length of -thioalkyl linkers, 
anchoring fast water exchanging Gd3+ chelates onto gold nanoparticles, on the relaxivity 
of the immobilized chelates. Gold nanoparticles functionalized with Gd3+ chelates of   
mercaptoundecanoyl and lipoyl amide conjugates of the DO3A-N-(-amino)propionate 
chelator were prepared and studied as potential CA for MRI. High relaxivities per 
chelate, of the order of magnitude 28-38 mM-1s-1 (30 MHz, 25 ºC) were attained thanks 
to simultaneous optimization of the rotational correlation time and of the water 
exchange rate. Fast local rotational motions of the immobilized chelates around 
connecting linkers (internal flexibility) still limit the attainable relaxivity. The degree of 
internal flexibility of the immobilized chelates seems not to be correlated with the 
length of the connecting linkers. Biodistribution and MRI studies in mice suggest that 
the in vivo behavior of the gold nanoparticles is determined mainly by size. Small 
nanoparticles (HD= 3.9 nm) undergo fast renal clearance and avoidance of the RES 
organs while larger nanoparticles (HD= 4.8 nm) undergo predominantly hepatobiliary 
excretion. High relaxivities, allied to chelate and nanoparticle stability and fast renal 
clearance in vivo suggests that functionalized gold nanoparticles hold great potential for 
further investigation as MRI Contrast Agents. This study contributes to understand the 
effect of linker length on the relaxivity of gold nanoparticles functionalized with Gd3+ 
complexes. It is a relevant contribution towards “design rules” for nanostructures 
functionalized with Gd3+ chelates as Contrast Agents for MRI and multimodal imaging.    
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Introduction 
MRI is becoming the “central imaging modality” in clinical diagnostic.1 MRI is 
based on the nuclear magnetic resonance phenomenon (NMR). In MRI scans, 
essentially, the relaxation times (T1 and T2) of the water protons of tissues (intrinsically 
different) are acquired and reconstructed into tridimensional anatomical images.2, 3 MRI 
is inherently non-invasive, makes use of (benign) non-ionizing radiation (static and 
radiofrequency magnetic fields), is depth independent and displays superb spatial 
resolution. Low detection sensitivity (inherent to the NMR phenomenon) is the main 
limitation of MRI.4 Contrast Agents (CA) are paramagnetic species (Gd3+, Mn2+, Fe3+, 
stable organic radicals, iron oxide nanoparticles, etc.) that by promoting  selective 
reduction of T1 or T2 of the water protons of tissues can generate dramatic contrast 
enhancements.5,6 The selective enhancement of the relaxation rates, R1,2, (R1,2 = 1/T1,2), 
normalized to 1 mM concentration of paramagnetic centres - relaxivity (r1,2, units mM
-1 
s-1), measures CA efficacy.4,7 Approved CA for clinical MRI are either Gd3+ complexes 
with linear (DTPA-type) and macrocyclic (DOTA-type) poly(aminocarboxylate) ligands 
(T1-weighed MRI)
8 or iron oxide nanoparticles (IONPS) stabilized with dextran (T2-
T2*-weighed MRI).
9 Low molecular weight Gd3+-based CA display relaxivities of the 
order of magnitude 3-5 mM-1 s-1 at magnetic fields relevant (currently) for clinical MRI 
(20-120 MHz). The Solomon-Bloembergen-Morgan (SBM) theory predicts that very 
high relaxivities, of the order of magnitude 100 mM-1 s-1 at magnetic fields relevant for 
clinical imaging (20-120 MHz), are attainable by Gd3+ chelates displaying simultaneous 
optimization of the main parameters that govern relaxivity: rotational correlation times 
(R), water exchange rate constant (kex) and electron relaxation parameters (v and 2).4,7 
Despite great advancements in the design and synthesis of CA during the past two 
decades, the ideal CA- displaying very high relaxivity and safety in vivo, targeting 
capability and responsiveness coupled to therapeutic properties, is still elusive.10 
The “nanotechnology revolution” is underway with a dramatic impact in many 
fields, particularly in medical imaging.11 Gold nanostructures (nanoparticles, 
nanoclusters, nanorods, etc) are finding many applications in chemistry, medicine, 
biotechnology and other fields,  owing to intrinsic reporting properties (localized 
surface plasmon resonance, fluorescence, X-Ray attenuation)12 coupled to therapeutic 
properties (hyperthermia, X-ray sensitization),13 biocompatibility and safety in vivo14 
and facile preparation with tunable size and surface properties by bottom-up 
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methodologies.15 The first generation of gold nanoparticles (AuNPs) CA made use of, 
easy to synthesize, thiol-functionalised Gd(DTPA-bis-amide)16-18 and Gd(DO3A)-type 
chelates.19 Superb relaxivities (per nanoparticle) were attained thanks to chelate 
clustering.16 In vivo MRI studies established the merits of AuNPs as CA for MRI, 
bimodal MRI/X-ray imaging and as theragnostics (MRI/X-ray sensitization).16-18,20 
Slow water exchange and fast local rotational motions of the immobilized chelates 
around linkers/spacers (chelate flexibility) result in relaxivity enhancements (per 
chelate) lower than those expected for Gd3+ chelates appended to rigid nanosized 
objects.16-18,21,22 Helm and co-workers reported very high relaxivity per chelate 
immobilized onto AuNPs (60 mM-1 s-1; 30 MHz, 25 ºC), attributed to two exchanging 
inner sphere water molecules in Gd(DTTA)-type chelates and complete rigidity of the 
chelates immobilized via a short aromatic linker.23 The relaxivity was however, still 
limited by slow water exchange. We have demonstrated in previous studies that the 
Gd[DO3A-N-(-amino)propionate] chelate and Gd3+ complexes of amide conjugates of 
the DO3A-N-(-amino)propionate chelator display water exchange rates within the 
range considered ideal for attaining high relaxivities at intermediate fields, thanks to 
“steric compression around the water binding site”.24,25,26 AuNPs functionalized with the 
fast water exchanging chelate Gd[DO3A-N-(-cystamido)propionate] display high 
relaxivities at intermediate and high fields (27 and 8.0 mM-1 s-1; 20 and 200 MHz, 
respectively, 25 ºC) as the result of simultaneous optimization of the rotational 
dynamics and water exchange rate.27 Fast local rotational motions around the cysteine 
linker still limit the attainable relaxivity, as demonstrated before for other 
macromolecular/nanosized objects such as micelles, dendrimers, polymers, etc.26,27,28 In 
this work we address the effect of the length of the -thioalkyl linker, anchoring fast 
water exchanging Gd[DO3A-N-(-amido)propionate] chelates to gold nanoparticles, on 
the relaxivity. Biodistribution and in vivo MRI studies with the functionalized AuNPs as 
CA are reported also.  
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Synthesis and characterization 
 
Mercaptoundecanoyl and lipoyl conjugates of the DO3A-N-(-amino)propionate 
chelator were synthesized to study the effect of the length of the -thioalkyl linker on 
the relaxivity of AuNPs functionalized with Gd3+ chelates  (Scheme1).  
 
Scheme 1. Synthetic pathway for -thioalkyl conjugates of the DO3A-N-(-amino)propionate chelator: 
a) K2CO3/MeCN;  b) ethyl bromoacetate, K2CO3/MeCN; c) i. TFA/CH2Cl2, ii. DIPEA/CH2Cl2, lipoic 
acid, DCC/HOBt; d) i) TFA/DCM, ii. Ethyl bromoacetate, K2CO3/MeCN; e) i. NaOH aq., ii. Flash 
chromatography silica gel, iii. SEM (Sephadex G10); f) GdCl3.6H2O; g) i. HAuCl4, NaBH4, ii. 
GdCl3.6H2O, iii. SEM (Sephadex G10) followed by dialysis (cellulose tubing MWCO 10 KDa).     
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The lipoic acid conjugate (L1) was prepared following the synthetic 
methodology reported before for the cysteine conjugate of the DO3A-N-(-
amino)propionate chelator (L3).27 The synthetic pathway excludes, all along, acidic 
conditions likely to promote oligomerization of the chelator through the lipoic acid 
moiety.29 Deprotection of the fully alkylated orthogonally protected intermediate 6 
allows direct conjugation of lipoic acid to the preformed DO3A-N--(amino)propionate 
scaffold.27 For preparing the 11-mercaptoundecanoyl conjugate (L2) the preformed 
amide was introduced into the cyclen scaffold via Michael addition of the N-Boc,N-(11-
(acetylthio)undecanoyl)dehydroalanine methyl ester electrophile (3).25,26 Reactive block 
3 was prepared over 3 steps in 48 % overall yield (Scheme 2).30  
 
Scheme 2. Synthetic route for Michael electrophile N-Boc,N-(11-(acetylthio)undecanoyl)dehydroalanine 
methyl ester (3): a) acetic anhydride/pyridine; b) serine methyl ester hydrochloride, HOBt/DCC/NEt3; c) 
Boc2O/DMAP, dry acetonitrile. 
 
The thioacetyl protecting group proved easy to install and stable under mild 
alkaline and strong acidic conditions en route to L2. Final deprotection was performed 
in one step by saponification with ethanolic NaOH. Following pH adjustment to 
neutrality with diluted hydrochloric acid, chelators L1 and L2 were adsorbed onto silica 
and purified by flash chromatography followed by Size Exclusion Chromatography 
(SEC) on Sepahdex G10 with water elution.  
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Relaxometric studies of GdL1 and GdL2 
 
The concentration dependence of the paramagnetic longitudinal water proton 
relaxation rate (R1p) was measured for GdL1 and GdL2 (20 MHz, 25 ºC, pH 7.1) (Figure 
1). 
 
  
Figure 1. Concentration dependence of the paramagnetic water proton relaxation rate R1p = (R1obs-R1d) for 
GdL1 (■) and GdL2 (●) (20 MHz, 25 ºC, pH 7.1).  
 
The relaxation rate data for GdL1 can be well fitted to a straight line (Equation 
1) affording a relaxivity of 8.6±0.9 mM-1 s-1 (20 MHz, 25 ºC, pH 7.1), characteristic of  
low/intermediate molecular weight chelates in fast rotation in solution. Fitting the 
relaxation rate data of GdL2 requires two straight lines with different slopes (Equation 1 
and 2). The concentration at the interception of the two lines defines the critical micelle 
concentration- cmc (cmc = 1.5 ± 0.3 mM).31 
 
𝑅1𝑝 = 𝑅1
𝑜𝑏𝑠 − 𝑅1
𝑑 = 𝑟1
𝑛𝑎 × 𝑐𝐺𝑑    Eq. 1 
𝑅1𝑝 = 𝑅1
𝑜𝑏𝑠 − 𝑅1
𝑑 = (𝑟1
𝑛𝑎 − 𝑟1
𝑎)cmc + r1
a × cGd  Eq. 2 
  
R1
obs is the longitudinal relaxation rate measured for the solution, R1
d is the 
diamagnetic contribution to the longitudinal relaxation rate (the relaxation rate of pure 
water) and CGd is the analytical Gd
3+ concentration. 
Below the cmc GdL2 is present in solution as monomers (non-aggregated), 
displaying a relaxivity (r1
na = 6.6 ± 0.1 mM-1 s-1; 20 MHz, 25 ºC, pH 7.1) characteristic 
of low molecular weight chelates (Equation 1).  
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For GdL2 at concentrations above the cmc the relaxation rate has a contribution 
from monomers (at a concentration equal to the cmc value) and from the (aggregated) 
micellar form (r1
a= 15.1 ± 0.8 mM-1 s-1; 20 MHz, 25 ºC, pH 7.1) (Eq. 2). Self-association 
of GdL2 into micelle-type structures leads to an increase of the effective molecular 
volume of the chelate. Slow tumbling in solution (longer rotational correlation times) 
translates into substantially higher relaxivity for the aggregated form of GdL2 
comparing to its monomeric (non-aggregated) form. The relaxivity enhancement for 
GdL2 upon self-assembly is of the same order of magnitude as that reported for the 
DOTA-type Gd(DOTASA-C12) chelate functionalized with a C12 alkyl chain (r1
a = 18.0 
mM-1 s-1, 20 MHz, 25 ºC)32, but significantly lower than that attained by the aggregated 
form of the fast water exchanging Gd[DO3A-N-(-pyrenebutanamido)propionate] 
chelate (GdL4 in Scheme 1) (r1
a = 32 mM-1 s-1; 20 MHz; 25 ºC).26 The temperature 
dependence of the water proton longitudinal relaxation rate for GdL1 and GdL2 (20 
MHz, 25 ºC) (Figure SI1) indicates that the relaxivity is not limited by slow water 
exchange, as demonstrated before for other Gd3+ chelates of amide conjugates of the 
DO3A-N-(-amino)propionate chelator.24,27   As both GdL2 and Gd[DO3A-N-(-
pyrenebutanamido)propionate] chelates display fast water exchange, the lower 
relaxivity attained by GdL2 has to be ascribed to higher internal flexibility and/or 
smaller size of the GdL2 micelles (Figure SI2). The pH dependence of the proton 
relaxation rate (Figure SI3) and the transmetallation study  (Figure SI4) show that GdL1 
and GdL2 are stable in the physiological pH range and kinetically inert towards 
transmetallation against Zn2+.33 
 
Preparation of gold nanoparticles functionalized with GdL1 and GdL2 chelates 
 
A modified Brust´s methodology in aqueous solution was employed for 
preparing AuNPs functionalized with GdL1 and GdL2 chelates.27,34 Using directly the 
GdL1 and GdL2 chelates as nanoparticle stabilizers resulted in extensive precipitation 
upon addition of the reducing agent (NaBH4). Attempts to functionalize citrate-
stabilized AuNPs with GdL1 and GdL2 chelates via place exchange revealed also 
unsuccessful.18 A two-step methodology, using the L1 and L2 chelators as NPs 
stabilizers, followed by Gd3+ complexation, revealed successful for preparing AuNPs 
functionalized with GdL1 and GdL2 chelates (Scheme 1).27 
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Solutions containing equimolar amounts of L1 or L2 and HAuCl4 turned 
immediately dark brown upon addition, in one aliquot, of one molar equivalent of 
NaBH4. Adding a molar equivalent of Gd
3+, in relation to the total amount of L1 or L2 in 
the crude mixture, resulted in stable NPs. Size Exclusion Chromatography (SEC) 
(Sephadex G10, elution with water) followed by extensive dialysis against water 
(cellulose tubing MWCO 10 000), afforded stable AuNPs functionalized with GdL1 and 
GdL2 chelates. A single fraction, including the broad colored band eluting on SEC, was 
collected. The absence of (free) uncomplexed Gd3+ was confirmed by the xylenol 
orange test.35  
 
Characterization of GdL1@AuNPs and GdL2@AuNPs preparations 
 
The Gd content of the functionalized AuNPs was estimated by bulk magnetic 
susceptibility measurements36 and further confirmed by ICP-OES following sample 
digestion with aqua regia (HCl/HNO3; 3/1 v/v) (Table 1).
27,37 
The AuNPs were characterized regarding size distribution by Dynamic Light Scattering 
(DLS) (Figure 2) and Transmission Electron Microscopy (TEM) (Figure 3). 
 
 
 
Figure 2. Size distribution (% volume) for GdL1@AuNPs (A) and GdL2@AuNPs (B).  
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Figure 3. Transmission Electron Microscopy (TEM) for GdL1@AuNPs (A) and GdL2@AuNPs (B).  
 
DLS measurements give the hydrodynamic diameter (HD) of NPs, including the 
Au nanocrystal core, the chelate monolayer and the immobile ionic layer surrounding 
the NPs. An average HD of 4.8 nm (NPs distribution in the range 3-10 nm with a 
maximum at 3-4 nm) and 5.9 nm (NPs distribution in the range 2-11 nm with a 
maximum at 4-5 nm), was measured for GdL1@AuNps and GdL2@AuNPs, 
respectively. TEM measurements reveal only the nanocrystal core. The TEM images 
obtained for GdL1@AuNPs and GdL2@AuNPs do not allow to determine the average 
diameter of the Au core owing to the very small size of the NPs. From the TEM images 
one can only conclude that most GdL1@AuNPs and GdL2@AuNPs have a nanocrystal 
core with a diameter under 2 nm. The average diameter of the Au core of 
GdL1@AuNPs and GdL2@AuNPs (~ 1.0 and 0.9 nm, respectively) was estimated from 
the DLS measurements taking into account the thickness of the chelate monolayer, 
calculated by PM6 semi-empirical calculations for the most likely conformations of 
GdL1 and GdL2 bonded to one or two Au atoms (1.9 and 2.5 nm, respectively) (Figure 
SI5, Table SI2).23,24 The absence of a well-defined plasmon absorption band in the UV-
Vis spectra of GdL1@AuNPs and GdL2@AuNPs (Figure SI6 and SI7), corroborates the 
very small size of the NPs core.38  
 
 
 
A B 
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Table 1. Characterization of GdL1@AuNPs and GdL2@AuNPs 
 GdL1@AuNPs
a GdL2@AuNPs
a
 GdL3@AuNPs
b 
[Gd] (mM)c 0.57  1.30  1.24 
 HD (nm)d 4.8 5.9 3.9 
Zeta potential (mV) -6.3 -13,7 -12.3 
DAu
e 1.0  0.9 0.7f 
aThis work; bRef 27; cDetermined by ICP-OES; dDLS measurements; eEstimated from the HD and 
semi-empirical calculations of the chelate monolayer thicknes- see Table SI2; f Revised value 
according to semi-empirical calculations for the length of GdL3. 
 
As L1, L2 and L3 share the same coordination cage, the length of the linker 
defines the overall wedge-like geometry of the chelator. Shorter linkers originate bulkier 
thiol ligands. Ligand bulkiness decreases in the series L3>L1>L2 (Figure SI5). Bulkier 
thiols are likely to terminate the growth of AuNPs earlier than less bulky ligands, 
resulting in AuNPs displaying smaller Au cores associated to higher surface curvature.39 
This correlation (DAu = 1.0, 0.9 and 0.7 nm, for GdL1, GdL2 and GdL3@AuNPs) is 
followed roughly by L2 and L3. The discrepancy observed for L1 can be due to the 
different sulfur binding mode.  
GdL1@AuNPs and GdL2@AuNPs were found to be stable in solution for 
extended periods. The NPs could be freeze-dried and re-dissolved without 
aggregation/precipitation. This can be ascribed to the overall negative charge (-1) of the 
immobilized Gd3+ complexes, resulting in NPs displaying negative zeta-potential 
(Figure SI8).  
 
Relaxometric characterization of GdL1@AuNPs and GdL2@AuNPs 
 
The concentration dependence of the proton longitudinal relaxation rate (R1p) 
was evaluated for GdL1@AuNPs and GdL2@AuNPs (r1 = 29 and 38 mM
-1 s-1, 
respectively, 20 MHz, 25 ºC, pH 7.1) (Figure SI9).  
For relevant clinical applications chelates immobilized onto NPs must be stable 
regarding demetallation and inert towards transmetallation with physiological metal 
ions, mainly Zn2+.33  In addition to releasing toxic Gd3+, demetallation and 
transmetallation processes of immobilized chelates are likely to trigger particle 
aggregation and precipitation in vivo. Stability at low pH is particularly important as 
protonation-assisted mechanisms have been implicated in demetallation, presumably 
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followed by transmetallation with serum ions, of macrocyclic Gd(DOTA)-type 
chelates.33,40,41 The pH dependence of the protonic relaxation rate (R1p) was evaluated 
for GdL1@AuNPs and GdL2@AuNPs in the pH range 3-10 (Figure SI10).  
The kinetic stability of the immobilized chelates (and entire nanoparticles) was 
evaluated by challenging GdL1@AuNPs and GdL2@AuNPs with Zn2+ ions in 
phosphate buffer (Figure SI11 and Figure SI12).33 According to the criteria set by 
Muller and co-workers, the immobilized chelates (and whole NPs) can be classified as 
kinetically inert and thermodynamically stable.33 The pH stability and kinetic inertness 
indicate that the NPs are potentially safe for in vivo applications. 
 
Nuclear Magnetic Relaxation Dispersion Profiles  
  
The magnetic field dependence of the proton relaxivity (r1) (Nuclear Magnetic 
Relaxation Dispersion - NMRD profiles) was obtained for GdL1@AuNPs and 
GdL2@AuNPs in the Larmor frequency range 0.01-400 MHz. The most important 
parameters that govern relaxivity are the hydration number (q), the water exchange rate 
constant (kex), the rotational correlation time (R) and the electron relaxation parameters 
(v and 2).4,7 The number of water molecules in the first coordination sphere, the water 
exchange rate and the rotational correlation time can be tuned by chelate design. Clear 
rules to tune the electron relaxation parameters are still elusive.42 Treating chelates 
immobilised onto macromolecular/nanosized objects (micelles, proteins, polymers, 
dendrimers, nanoparticles, viral particles) as rigid entities, often fails to deliver reliable 
parameters from the fitting of the NMRD profiles to the SBM theory. In fact, it is 
necessary to assume in the fittings that the interactions that generate the relaxation are 
influenced by both fast local rotational motions (Rlocal) of the immobilized chelates 
around linkers/spacers and a slower, global motion, common to the entire object 
(Rglobal). The degree of spatial restriction of the local motion (interpreted as chelate 
flexibility), is measured by the generalized, model independent order parameter- S2. The 
order parameter can assume values in the range 0-1: S2= 0 if the internal motions are 
isotropic, S2= 1 if the internal motions are completely restricted.43 
In this work, it was assumed in the fittings that the immobilised GdL1 and GdL2 
complexes have one inner sphere water molecule (q = 1) like other Gd3+ complexes of 
the DO3A-N-(α-amino/amido)propionate family.24-26 The water exchange rate constant 
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and its activation enthalpy (kex
298, H‡) were fixed to values determined for the 
analogous Gd[(DO3A-N-(-benzoylamido)propionate] chelate.25  
The fittings (continuous lines in Figure 4) are restricted to frequencies above 6 
MHz as the SBM theory is not suitable for describing the rotational dynamics of slow-
rotating objects at low magnetic fields. The best fit parameters for GdL1@AuNPs and 
GdL2@AuNPs, obtained from the analysis of 1H NMRD data, are represented in Figure 
4 and summarized in Table 2. 
 
 
Figure 4.  1H Nuclear Magnetic Relaxation Dispersion (NMRD) profiles for: A- GdL1@AuNPs (0.56 
mM; pH 7.0) 25 °C (■) and 37 °C (●); B- GdL2@AuNPs (1.30 mM; pH 7.0); 25 °C (○) and 37 °C (□). 
The fitted curves are represented as continuous lines. The broken lines are the result of simulations using 
the same parameters as in Table 2, but assuming total rigidity (S2= 1) of the immobilized chelates.  
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Table 2. Best fit parameters obtained for GdL1@AuNPs and GdL2@AuNPs from the fitting of the 1H 
NMRD profiles to the SBM theory, including the Lipari-Szabo approach for internal flexibility. 
 
 GdL1@AuNPs GdL2@AuNPs 
Parameters Value Value 
q 1 1 
H‡ [J/mol] 17 17 
kex298 [107 s-1] 5.14 5.14 
ER [kJ/mol] (global) 19.4±1.1 18±3.6 
RH298[ps] (global) 1900±140 3500±940 
ER [kJ/mol] (local) 20 18 
RH298[ps] (local) 460±50 970±230 
S2 0.41 ± 0.04 0.42±0.12 
EV [kJ/mol] 1 1 
V298 [ps] 27±4 17± 3 
EH298 [10-10 m2 s-1]  23 23 
EDGH [kJ/mol] 20 20 
Gd-O [Å] 2.5 2.5 
2 [1020 s-2]  0.044±0.002 0.065±0.004 
Gd-HW 1st [Å] 3.1 3.1 
Gd-HW 2nd [Å] 3.6 3.6 
 
Table 3. Selected molecular parameters for GdL1@AuNPs and GdL2@AuNPs and other systems 
reported in the literature and discussed in the manuscript. 
 
 
 
Parameter GdL1@AuNPs
a GdL2@AuNPsa GdL3@AuNPsb GdL4c 
q 1 1 1 1 
kex298 [107 s-1] 5.14 5.14 5.14 6.2  
g298 [ps] 1900  3500 2470  3780 
lo298 [ps] 460  970 177  930 
S2 0.41 0.42 0.48  0.24 
HD (nm)d 4.8 5.9 3.9 49e 
r1  (mM -1 s-1) 
 27f,h 
 
38f,h 
 
28f,h 
 
32g,h 
11.2f,i 8.4f,i 
 
8.5f,i n.d. 
a This work; bRef 27; cRef 26; d From DLS measurements; eZ-average from a bimodal distribution of  particles; 
f Relaxivity per chelate; g Relaxivity of the aggregated form; h 20 MHz, 25 ºC; i  200 MHz, 37 ºC. 
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The NMRD profiles are characteristic of macromolecular objects in slow 
rotation, confirming the immobilization of the GdL1 and GdL2 chelates onto gold 
nanocrystals: a plateau in the frequency range 0.01 to 1 MHz, a simple dispersion at 
about 1-10 MHz and a broad hump centered at 20-60 MHz.  
The AuNPs prepared in this work display exceptional relaxivities (per Gd3+ 
chelate) (r1max = 27 and 38 mM
-1 s-1 for GdL1@AuNPs and GdL2@AuNPs, respectively; 
30 MHz, 25 ºC), much higher than those reported by other authors for AuNPs 
functionalized with monoaquated (q = 1) Gd3+ complexes.16,19,21 The temperature 
dependence of the relaxivity, higher relaxivity at lower temperature, for both 
GdL1@AuNPs and GdL2@AuNPs, indicates that the water exchange rate is not limiting 
the relaxivity. The superb relaxivities attained can be ascribed to simultaneous 
optimization of the water exchange rate (fast water exchange regime) and of the 
rotational correlation time. The value obtained for the order parameter (S2 ~ 0.40) 
indicates that fast local motions of the chelates anchored onto the Au core are still 
limiting the relaxivity. Simulations, using the same parameters as on Table 3, but 
assuming total rigidity of the immobilized chelates (S2 = 1), afford much higher 
relaxivities (of the order of magnitude 60 mM-1 s-1; 20 MHz; 25 ºC) for GdL2@AuNPs. 
The higher relaxivity attained by GdL2@AuNPs, comparing to GdL1@AuNPs and 
GdL3@AuNPs, has to be ascribed to its significantly larger global rotational correlation 
time (Rg), reflecting the larger size (hydrodynamic diameter) of the GdL2@AuNPs 
nanoparticles. In fact, the length of the thioalkyl linker seems not to have much 
influence on the internal flexibility of the immobilized chelates: the order parameter S2 
is identical for GdL1@AuNPs and GdL2@AuNPs, despite the longer linker anchoring 
GdL2 to the Au core. Moreover, the shorter cysteine linker anchoring GdL3 to the Au 
core (possibly in a bidentate (N, S) fashion similar to GdL1 (S,S)), results only in 
slightly higher rigidity of the immobilized chelates. Despite the limiting effect of the 
internal rotational motions, chelate immobilization onto AuNPs results in relaxivity 
enhancements of more than 300% for GdL1 and over 500% for GdL2 (comparing to its 
monomeric form), attributed to simultaneous optimization of R and kex. Moreover, 
GdL2 immobilized onto AuNPs displays substantially higher relaxivity than the 
aggregated (micellar) form of GdL2 (38 vs 15 mM-1 s-1; 20 MHz, 25 ºC).  The micellar 
form of the Gd[DO3A-N-(-pyrenebutanamido)propionate] chelate (GdL4) (sharing the 
same coordination cage with GdL1,2,3) is significantly more flexible (S2= 0.24 vs 0.42) 
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than the Au-anchored GdL1 and GdL2 chelates. Accordingly, GdL2@AuNPs, displaying 
a Rg value similar to the aggregated form of  GdL4, exhibits higher relaxivity (38 vs 32 
mM-1 s-1; 20 MHz, 25 ºC, for GdL2@AuNPs and for the aggregated form of GdL4, 
respectively).26 
Covalent immobilization of Gd3+ chelates onto AuNPs seems more effective in 
attaining high relaxivities, than chelate self-assembly into micelle-type structures, 
owing to higher restriction of internal rotational motions.  
The work reported here addresses explicitly the effect of linker length on the 
relaxivity of AuNPs functionalized with Gd3+ chelates, contributing to the “rational 
design” of nanomaterials as CA for MRI/multimodal imaging.44 
 
Biodistribution studies  
The biodistribution of [153Sm]L1@AuNPs in Wistar rats was obtained at 2 and 
24 hours post-injection (Figure 6). 
 
 
Figure 6. Biodistribution of [153Sm3+]L1@AuNPs in Wistar rats, stated as percent of injected dose per 
gram of organ (% ID/ g): a) 2 and b) 24 hour post-injection. Inset - time evolution of the activity in the 
blood. The results are from a group of four animals in each experiment. 
 
The activity in the blood was measured after 30 minutes, 60 minutes, 2 and 24 
hours (inset in Figure 6) revealing fast clearance of activity from the blood with a 
reduction of approximately 50% between 30 minutes and two hours. After 2 hours post-
injection, the NPs are mainly found in the organs of the reticulo-endothelial system 
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(RES), liver and spleen, and to a lesser extent in the blood and lungs. These results 
suggest that the nanoparticles are cleared mainly by phagocytosis by the macrophage 
rich organs, liver and spleen, with a less important contribution from renal 
elimination.20,26,45 This is in accordance with what was found by MRI for 
GdL1@AuNPs (see below). 
At 24 hours post-injection significant activity is found only in the organs of the 
reticulo-endothelial system, RES. The activity approximately doubled in the spleen, 
showing only a slight increase in the liver. The activity in the bones at 24 hours post-
injection is very low, suggesting that the rate of chelate demetallation and formation of 
insoluble metal colloids in vivo is very low.  
 
MRI Studies 
 
MRI studies were performed in male Swiss mice (~ 20 g) in a preclinical 
imaging platform (PharmaScan) operating at 7.0 Tesla (300 MHz). A Dynamic Contrast 
Enhancement (DCE) study was performed with GdL1@AuNPs (0.1 mmol Gd/kg body 
weight) and GdL3@AuNPs (0.1 and 0.05 mmol Gd/kg body weight) and for 
comparison purposes with Gd(DTPA) (Magnetvist®, Bayer) at the same doses (Figure 
7). Figure 7 shows a representative series of T1-weighted spin-echo coronal images. In 
the pre-injection images, the kidney structures (cortex, inner and outer medulla) and 
adjacent tissues appear dark. After bolus injection in the vascular system, a strong signal 
enhancement was observed in the kidneys for Gd(DTPA), GdL1@AuNPs and 
GdL3@AuNPs as result of T1 shortening. A much slighter signal enhancement was 
observed in the liver. Both NPs follow mainly renal elimination by glomerular filtration, 
with significant hepatobiliary contribution to excretion seen for GdL1@AuNPs only.  
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Figure 7. Representative coronal T1-weighted spin echo MR images of mice before and after injection of 
contrast agents: (A) Gd(DTPA) (0.1 mmol Gd kg-1 BW), (B) GdL1@AuNPs (0.1 mmol Gd kg-1 BW), (C) 
GdL3@AuNPs (0.1 mmol Gd kg-1 BW); (D) Gd(DTPA) (0.05 mmol Gd kg-1 BW), (E) GdL3@AuNPs 
(0.05 mmol Gd kg-1 BW). 
 
The time course of the average intensity (mean values of groups of four animals) 
within different regions of interest (ROIs) placed on the several organs (Figure 8) 
allows to understand better the features of Figure 7. 
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Figure 8. Time course of signal intensity, up to 60 min post-injection,  for several regions of interest, 
relative to the initial value, during dynamic contrast enhancement MRI experiments in rats administrated 
with: (A) Gd(DTPA) (0.1 mmol kg-1 BW) and (B) GdL1@AuNPs (0.1 mmol kg-1 BW), (C) 
GdL3@AuNPs (0.1 mmol kg-1 BW); (D) Gd(DTPA) (0.05 mmol kg-1 BW); (E) GdL3@AuNPs (0.05 
mmol kg-1 BW). The time courses are data from mean values of four animals. 
 
In order to compare the results for all the animals under study (n = 4), the data 
were normalized by calculating the mean relative enhancement of each ROI. The 
scattering in the time course curves was caused by animal respiratory motion. The 
relative enhancement obtained with Gd(DTPA) at 0.1 mmol kg-1 BW dose (Figure 8A), 
increased almost immediately after intravenous injection, from 0 up to about 160% in 
the kidney medulla and 100% in the kidney cortex, followed by a steady decrease to 
values around 60% and 30%, respectively, within 60 minutes. This time course is in 
agreement with the literature for the Gd(DTPA) and Gd(DOTA) low molecular weight 
CA.46,47 
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The enhancement profiles of GdL1@AuNPs (Figure 8B) and GdL3@AuNPs 
(Figure 8C) at 0.1 mol Gd kg-1 BW dose are considerably different from the 
enhancement profile of Gd(DTPA) at the same concentration: there is an immediate 
enhancement of the kidney structures (cortex and medulla) followed by a steady liver 
enhancement. For GdL3@AuNPs at 0.1 mmol Gd kg-1 BW dose (Figure 8C) is 
noticeable a fast and strong enhancement of the kidney medulla and kidney cortex        
(~150%) which slowly decreases to ~100% over the time course of the experiment. A 
much lower muscle and liver enhancement is also noticeable. Reducing the dose of 
GdL3@AuNPs to 0.05 mmol Gd Kg-1 BW results in an imaging profile virtually 
equivalent to Gd(DTPA): fast renal elimination with negligible hepatobiliary 
contribution (Figure 8D and 8E for Gd(DTPA) and GdL3@AuNPs, respectively). There 
is a fast enhancement of the kidney cortex (~150 % at 20 minutes) which steadily 
decreases over the time course of the experiment.  These results strongly suggest that 
while GdL1@AuNPs is mostly eliminated through hepatobiliary excretion, or is taken 
up by resident macrophages (Kupfer cells) in liver, GdL3@AuNPs behaves in vivo as a 
low molecular weight CA following mainly renal elimination. The steady, liver and 
presumably spleen enhancement observed with GdL1@AuNPs is in sharp contrast to 
the “clean” renal elimination observed for GdL3@AuNPs. This behaviour can only be 
explained by the difference in size between GdL1@AuNPs and GdL3@AuNPs- average 
HD 4.8 and 3.9 nm, respectively, stressing the complex interplay between the physical-
chemical properties of nanostructures and in vivo behaviour.  
The animal MRI studies were performed at high field (300 MHz, 7 Tesla). This study 
illustrates the mismatch between the performance of macromolecular/nanosized CA, 
optimized for intermediate fields (20-60 MHz), and the trend for increasingly higher 
magnetic field imagers. The overwhelming advantage of the AuNPs, over low 
molecular weight CA at intermediate fields (20-60 MHz), is partially eroded at higher 
magnetic fields (Figure 4).48 Nonetheless, the AuNPs studied in this work still exhibit 
relaxivities significantly higher than Gd(DTPA) at high fields (11.2, 8.4 vs ~ 2 mM-1 s-1 
for GdL1@AuNPs and GdL2@AuNPs, respectively, and Gd(DTPA), 200 MHz, 25 ºC ). 
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Conclusions 
  In this work we extend the synthetic methodologies developed before for AuNPs 
functionalized with stable fast water exchanging Gd3+ chelates as high relaxivity, 
potentially safe CA for in vivo MRI. Two novel ligands were designed to investigate the 
role of the length of the -thioalkyl linker, anchoring the coordination cage to the gold 
nanocrystal, on the relaxivity. Superb relaxivities at magnetic fields relevant for clinical 
imaging (27 and 38 mM-1 s-1, 30 MHz, 25 ºC, for GdL1@AuNPs and GdL2@AuNPs, 
respectively) were obtained attained thanks to simultaneous optimization of the 
rotational correlation time and of the water exchange rate. Relaxivities, still relevant for 
clinical high field applications (of the order of magnitude 10 mM-1 s-1; 200 MHz, 37 ºC) 
were attained also. The relaxivity is still limited by internal flexibility of the 
immobilized chelates. The degree of internal flexibility of the immobilized chelates 
(measured by the order parameter S2) seems not to be determined by the length of the 
linker, presumably owing to the high surface curvature of the NPs. A MRI study in mice 
demonstrated that while GdL3@AuNPs (HD = 3.9 nm) behaves in vivo much like the 
low molecular weight CA Gd(DTPA), undergoing fast renal elimination without liver 
(and presumably spleen) uptake, GdL1@AuNPs (HD = 4.8 nm) shows considerable 
hepatobiliary contribution to elimination. A biodistribution study in rats using the 
surrogate 153SmL1@AuNPs tracer confirmed extensive activity uptake and 
accumulation over time in the liver and spleen.  
The GdL3@AuNPs CA, amenable to further elaboration with targeting moieties, 
seems particularly promising for in vivo MRI applications. 
The work reported is a relevant contribution towards the design of nanomaterials 
functionalized with Gd3+ chelates as very high relaxivity/multimodal CA for MRI.44 
   
 
  
23 
 
Experimental  
Materials and methods 
  
Chemicals were purchased from Sigma-Aldrich and used without further 
purification. Cyclen was purchased from Chematech, France. Analytical grade solvents 
were used and not further purified, unless specified. Reactions were monitored by TLC 
on silica gel by examination under UV light (250 and 365 nm) and staining with iodine 
vapour and Ellman´s reagent. Preparative chromatography was carried out on Silica Gel 
60 (230-400 mesh). Ion exchange chromatography was performed on Dowex 1X2-100-
OH- (50-100 mesh) resin. Size Exclusion Chromatography (SEC) was performed on 
Sephadex G10 (40-120 m) with water elution. Dialysis was performed against water 
on cellulose membranes (MWCO 10 KDa). UV-VIS spectra were acquired with a 
Shimadzu UV-2501PC spectrophotometer. The size distribution and zeta potential of 
the AuNPs was determined with a Malvern Zetasizer, NANO ZS (Malvern Instruments 
Limited, UK), using a He-Ne laser (wavelength of 633 nm) and a detector angle of 173º. 
TEM experiments were performed with a JEOL JEM1200EXII microscope at Bath 
University, UK. Mass spectrometry was performed at CACTI - Vigo, Spain.  
1H and 13C NMR spectra were run on Varian Unity Plus 300, Bruker Avance-3 
400 Plus and Varian VNMRS 600 NMR spectrometers. Chemical shifts (δ) are given in 
ppm relative to the CDCl3 solvent (
1H, δ 7.27; 13C 77.36) as internal standard. For 1H 
and 13C NMR spectra recorded in D2O, chemical shifts (δ) are given in ppm, relative to 
TSP as internal reference (1H, δ 0.0) and tert-butanol as external reference (13C, CH3 δ 
30.29), respectively.  
 
Preparation of Lipoic acid conjugate DO3A-N-(α-lipoamido)propionate - L1 
 
Synthesis of ((5-(1,2-dithiolan-3-yl)-2-pentanamido)methoxycarbonylethyl)-4,7,10-
tris-(ethoxycarbonylmethyl) -1,4,7,10-tetraazacyclododecane - fully protected 
conjugate 7. 
Orthogonally protected compound 6 was synthesized as described before by 
us.27 A solution of compound 6 (85 mg; 1.12 mmol) in a mixture DCM/TFA (24 ml, 
3:1, v/v) was stirred at room overnight. The solvent was removed under reduced 
pressure, the residue was re-dissolved in DCM and the solvent was evaporated. This 
procedure was repeated several times.  
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The resulting oil was dried under vacuum to afford a white foam. 1H NMR (CDCl3) 
revealed the disappearance of the signals assigned to the Boc groups on compound 6. 
Quantitative deprotection was assumed. The residue (1.12 mmol, assuming quantitative 
deprotection) was dissolved in DCM (20 ml) and the solution was adjusted to pH 9-10 
(pH paper) by drop-wise addition of DIPEA. To this solution was added sequentially 
Lipoic acid (288 mg; 1.40 mmol), HOBt (214 mg; 1.40 mmol) and a solution of DCC 
(288 mg; 1.40 mmol) in DCM (5 ml). The solution was stirred at room temperature 
overnight. The DCU byproduct was removed by filtration and the reaction mixture was 
concentrated under reduced pressure. The residue was re-dissolved in ethyl acetate (100 
ml), and the solution was washed with NaHCO3 (50 ml, saturated solution) and brine 
(3x50 ml). The organic phase was dried (MgSO4) and concentrated under reduced 
pressure to afford the title compound (7) (358 mg; 44 %). 1H NMR (300 MHz, CDCl3): 
= 1.28 (m, 9 H, C(O)OCH2CH3), 1.48 (m, 2 H, NHC(O)CH2CH2CH2), 1.70 (m, 2 H, 
NHC(O)CH2CH2), 2.18 (m, 2 H, NHC(O)CH2CH2CH2CH2), 2.30 (m, 4 H, NHC(O)CH2 
and CHCH2CH2S), 2.60-3.60 (broad overlapped signals, integrating for 16 H, 
N(CH2)2N; 2 H, ABX; 2 H, CHCH2CH2S, 1 H, CHSCH2CH2S), 3.73 (m, 6 H, 
C(O)CH2N), 3.97 (s, 3 H, C(O)OCH3), 4.19 (m, 6 H, C(O)CH2CH3), 4.90 (dd,1 H, 
ABX). HRMS (ESI): m/z: cacd. for C32H58N5O9S2 [M+H]
+: 720.3676, found: 720.3645. 
 
Preparation of ((5-(1,2-dithiolan-3-yl)-2-pentanamido)carboxyethyl)-4,7,10-tris-
(carboxymethyl)-1,4,7,10-tetraazacyclododecane - fully deprotected DO3A-N-(-
lipoamido)propionate chelator (L1). 
Compound (7) (2.26 g, 3.15 mmol) was dissolved in a mixture water/ethanol (40 
ml, 1/1 v/v). The solution was adjusted to pH ~ 11 with aqueous NaOH 1 M (pH paper) 
and was left stirring at room temperature overnight. Then, the reaction mixture was 
adjusted to pH ~7 with hydrochloric acid 1 M (pH paper) and concentrated under 
reduced pressure. The residue was adsorbed onto silica and purified by flash 
chromatography (CH2Cl2CH2Cl2/EtOH 1/1EtOHEtOH/H2O 1/1H2O) to afford 
a light yellow foam. The final compond (L1) was further purified by size exclusion 
chromatography on Sephadex G10 (0.42 m) with elution with water. The conductivity 
of the collected fractions was measured and were also tested by TLC (ethanol/water 
(1/1), revelation with iodine vapor). The high conductivity fractions (salt) were 
discarded and the medium/low conductivity fractions showing a signal on the TLC were 
pooled, concentrated at room temperature and further dried under vacuum to afford the 
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final deprotected compound as a light yellow solid (L1) (0.685 g, 35%). 1H NMR (300 
MHz, D2O): = 1.46 (m, J= 7.8 Hz, 2 H, NHC(O)CH2CH2CH2), 1.64-1.72 (m, 6 H, 
NHC(O)CH2CH2, NHC(O)CH2CH2CH2CH2, CHCH2CH2S), 2.01 (m, 2 H, 
NHC(O)CH2), 2.34 (t, J= 7.5 Hz 2 H, CHCH2CH2S), 2.49 (m, 1 H, CHSCH2CH2S), 
2.10-3.40 (broad overlapped signals integrating to 16 H, 4 x N(CH2)2N, 6 H, 3x 
NCH2C(O) and 2H, ABX), 4.49 (m, 1 H, ABX). 
13C NMR (75.4 MHz, D2O): 25.02 (1 
C, CH2), 28.32 (1 C, CH2), 33.93 (1 C, CH2), 35.73 (1 C, CH2), 38.22 (1 C, CH2), 40.46 
(2 C, 2xCH2), 47.81 (3 C, 3xCH2), 49.46 (1 C, CH2), 51.37 (1 C, CHCH2), 51.94 (2 C, 
CH2), 54.51 (2 C, CH2), 56.08 (2 C, CH2), 56.76 (2 C, CH2), 170.94 (1 C, C(O), 176.65 
(2 C, 2xC(O), 177.36 (2 C, 2xC(O)). HRMS (ESI): m/z: cacd. for C25H44N5O9S2 
[M+H]+: 622.2580, found: 622.2572.  
 
Preparation of  11-mercaptoundecanoic acid conjugate DO3A-N-(-
mercaptoundecanamido)propionate - L2  
 
Synthesis of 11-(acetylthio)undecanoic acid  (10) 
 
 To an ice-cooled solution of 11-mercaptoundecanoic acid (9) (2.00 g, 9.17 
mmol) in pyridine (2.6 ml) was added acetic anhydride (2.6 ml, 2.81 g, 27.5 mmol). The 
solution was left stirring at room temperature overnight.  Ice was directly added to the 
reaction mixture, followed by magnetic stirring until complete melting of the ice.  The 
mixture was extracted with ethyl acetate (3×150 ml). The organic phase was washed 
with brine (3x30 ml), dried (MgSO4) and the solvent was removed under reduced 
pressure. The residue was further dried under vacuum to afford the final compound as 
an off-white solid (2.12 g, 89%). 1H NMR (400 MHz, CDCl3): δ= 1.27 (s (br),12 H, 
6×CH2), 1.58-1.52 (m, 2 H, SCH2CH2), 1.66-1.59 (m, 2 H, (CO2H)CH2CH2), 2.32 (s, 3 
H, C(O)CH3), 2.35 (t, J= 7.2 Hz, 2 H, CH2COOH), 2.86 (t, J= 7.2 Hz, 2 H, SCH2). 
13C 
NMR (100.62 MHz, CDCl3): δ= 24.61 (C(O)CH2CH2), 28.73 (SCH2),  28.97, 29.00, 
29.10, 29.13, 29.26, 29.32 (overlapped inner CH2 signals), 29.43 (SCH2CH2), 30.59 
(CH3),  33.99 (C(O)CH2),  179.89 (COOH),  196.11 (SC(O)Me). HRMS (ESI): m/z: 
calcd. for C13H24NaO3S [M+Na]
+: 283.1338, found.: 283.1339. 
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Synthesis of (11-(acetylthio)undecanoyl)serine methyl ester (11) 
 
 To an ice-cooled solution of compound 10 (2.12 g, 8.14 mmol) in acetonitrile 
(70 ml) was added HOBt (1.85 g, 8.95 mmol) and a solution of DCC (1.25 g, 8.14 
mmol) in acetonitrile (10 ml). The mixture was left stirring at the ice bath temperature 
and after 15 minutes L-serine methyl ester hydrochloride (1.27 g, 8.14 mmol) and 
triethylamine (1.13 ml, 0.82 g, 8.14 mmol) were added. The reaction mixture was left 
stirring at room temperature overnight. The DCU byproduct was removed by filtration 
and the sample was concentrated under reduced pressure. The residue was re-dissolved 
in ethyl acetate (100 ml) and the solution was washed sequentially with KHSO4 (1 M, 
3x50 ml), NaHCO3 (saturated solution, 50 ml) and brine (3x50 ml). The organic phase 
was dried (MgSO4) and concentrated under reduced pressure to afford title compound 
11 (2.73 g; 93%).1H-NMR (CDCl3, 400 MHz): δ= 1,25 (s (br), 12 H, 6 × CH2), 1.52-
1.57 (m, 2 H, SCH2CH2), 1.58-1.65 (m, 2 H, NHC(O)CH2CH2), 2.25 (t, J= 7.2 Hz, 2 H,  
NHC(O)CH2), 2.30 (s, 3 H, SC(O)CH3), 2.84 (t, J= 7.2 Hz, 2 H, SCH2), 3.76 (s, 3 H, 
OCH3),  3.87 (ddd, J= 3.6, 11.2, 29.8 Hz, 1 H, CHaHbOH), 3.96 (ddd, J= 4.0, 11.0 and 
29.8 Hz, 1 H, CHaHbOH),  4.67-4.63 (m, 1 H, CH), 6.62 (s (br), 1 H, NH). 
13C-NMR 
(CDCl3, 100.62 MHz): δ= 24.80 (NHC(O)CH2CH2), 28.67, 28.95, 29.06, 29.09 
(overlapped CH2 signals), 29.17 (SCH2), 29.25, 29.27 (overlapped CH2 signals), 29.37 
(SCH2CH2), 30.55 (SC(O)Me), 36.37 (C(O)CH2), 52.54 (OMe), 54.54 (CH), 63.20 
(CH2OH), 171.03 (C(O)OMe), 173.78 (NHC(O)), 196.19 (SC(O)).  
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Synthesis of N-(tert-butoxycarbonyl),N-(11-(acetylthio)undecanoyl) 
dehydroalanine methyl ester (3) 
 
 To a solution of compound (11) (0.866 g, 2.40 mmol) in dry acetonitrile (15 
ml) was sequentially added DMAP (0.081 g, 0.66 mmol) and Boc2O (1.44 g, 6.6 mmol). 
The mixture was left stirring for 5 days at room temperature. The reaction progress was 
monitored by 1H NMR. A small volume of reaction mixture was removed, worked-up 
was as described below, and analyzed by 1H NMR by monitoring the disappearance of 
the  signal of the intermediate carbonate ester and the appearance of the alkenic signals 
at = 5.62 and 6.44 ppm. The solid residues were removed by filtration and the sample 
was concentrated under reduce pressure. The residue was re-dissolved in ethyl acetate 
(150 ml), and the solution was washed sequentially with KHSO4 (1 M, 3x50 ml), 
NaHCO3 (saturated solution, 50 ml) and brine (3x50 cm
3). The organic phase was 
concentrated under reduced pressure and the residue was purified by a flash 
chromatography (n-hexane→n-hexane/ethyl acetate  (70:30)) to afford the title 
compound as a thick reddish oil (0.445 g, 58%).1H-NMR (CDCl3, 400 MHz) = 1.27 (s 
(br), 12 H, 6×CH2), 1.46 (s, 9 H, C(CH3)3), 1.49-1.57 (m, 2 H, SCH2CH2), 1.65 (m, 2 H, 
C(O)CH2CH2), 2.32 (s, 3 H, SC(O)CH3),  2.86 (t, J= 7.6 Hz, 2 H, NHC(O)CH2), 2.93 
(t, J= 7.6 Hz, 2 H, SCH2), 3.78 (s, 3 H, C(O)OCH3),  5.62 (s, 1 H, CCHaHb), 6.44 (s, 1 
H, CCHaHb). 
13C-NMR (CDCl3, 100.62 MHz): δ= 24.71 (C(O)CH2CH2), 27.40 
(SCH2CH2), 27.80 (3×OCCH3), 28.75, 29.05, 29.08, 29.11, 29.35, 29.44 (overlapped 
CH2 signals), 29.38 (C(O)CH2), 30.59 (SC(O)CH3), 37.66 (SCH2), 52.38 (C(O)OCH3), 
83.53 (OCCH3), 125.71 (CCH2), 135.56 (CCH2), 151.52 (NC(O)O), 163.68 
(C(O)OCH3), 175.66 (NC(O)), 196.00 (SC(O)). HRMS (ESI): m/z: calcd. for 
C22H37NaO6S [M+Na]
+: 466.2234, found: 466.2223. 
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Synthesis of (11-(acetylthio)-2-N-(tert-butoxycarbonyl)undecanamido-
methoxycarbonylethyl)-1,4,7,10-tetraazacyclododecane - monoalkylated cyclen (5) 
 
To a solution of cyclen (0.260 g, 1.5 mmol) in acetonitrile (30 ml) was added 
K2CO3 (0.83 g, 6.0 mmol) and in several portions compound 3 (0.445 g, 1.0 mmol). The 
suspension was vigorously stirred at room temperature for 4 hours. The suspended solid 
was removed by filtration and the solvent was evaporated under reduced pressure.  
The residue was purified by flash chromatography 
(CH2Cl2CH2Cl2/EtOH/NH3/H2O (70:30:5:5)) to the afford the title compound 5 as a 
white foam (0.451 g, 73.0 %).1H-NMR (CDCl3, 400 MHz): δ= 1.33 (s (br), 12 H, 
6×CH2), 1.47 (s, 9 H, OC(CH3)3), 1.60 (m, 2 H, C(O)CH2CH2), 1.60-1.65 (m, 2 H, 
SCH2CH2), 2.33 (s, 3 H, SC(O)CH3), 2.51-2.65 (m, 16 H, 4×N(CH2)2N), 2.74-2.79 (m, 
2 H, (NHC(O)CH2)), 2.74-2.79 (m, 1 H, NCHaCHbCH), 2.85 (t, J= 7.2 Hz, 2 H, 
CH3C(O)SCH2), 3.45 (dd, J= 5.2 and 14.4 Hz, 1 H, NCHaCHbCH), 3.68 (s, 3 H, 
C(O)OCH3), 5.46 (t, J= 5.2 Hz, 1 H, NCH2CH). 
13C-NMR (CDCl3, 100.62 MHz): δ= 
25.01 (C(O)CH2CH2), 27.90 (OCCH3), 28.75 (SCH2), 29.05, 29.10, 29.17, 29.37, 29.39, 
29.40 (overlapped CH2 signals), 29.43 (SCH2CH2), 30.58 (SC(O)Me), 40.06 
(C(O)CH2), 46.92 (6×NHCH2), 51.07 (2×CH2NCH2CH), 52.16 (C(O)OMe), 53.56 
(NCH2CH), 58.06 (NCH2CH), 83.99 (C), 151.96 (NC(O)O), 170.84 (C(O)OMe), 
175.52 (N(Boc)C(O)CH2), 195.99 (SC(O)). HRMS (ESI): m/z: calcd. for C30H58N5O6S 
[M+H]+: 616.4102, found.: 616.4100. 
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Synthesis of (11-(acetylthio)-2-undecanamido-methoxycarbonylethyl)-4,7,10-tris-
(ethoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane - fully alkylated cyclen (8) 
A solution of monoalkylated cyclen 5 (0.451 g, 0.87 mmol) in trifluoroacetic 
acid in dichlorometane (33%, 24 ml) was stirred overnight at room temperature. The 
solvent was evaporated at reduced pressure and the residue was re-dissolved in 
dichlorometane. The solvent was evaporated again, and this procedure was repeated 
several times to give a light thick yellow oil which was further dried under vacuum. 1H 
NMR spectroscopy (CDCl3) revealed the disappearance of the signal assigned to the 
Boc group in the precursor compound 5. The deprotected compound (0.87 mmol, 
assuming quantitative deprotection) was re-dissolved in MeCN (20 ml), K2CO3 (1.17 g, 
8.46 mmol) was added and the suspension was left under vigorous stirring at room 
temperature for 30 minutes. Ethyl bromoacetate (0.29 ml, 2.61 mmol) was added, and 
the suspension was further stirred for 2 hours. The suspended solids were removed by 
filtration, the solvent was evaporated under reduce pressure and the residue was purified 
by flash chromatography (CH2Cl2 CH2Cl2/EtOH (7:3)) to afford compound 8 (0.218 
g, 32 %) as a white foam.  
1H-NMR (CDCl3, 400 MHz): δ= 1.33 (m, 12 H, 6×CH2), 1.47 (s, 9 H, OC(CH3)3), 1.60 
(m, 2 H, C(O)CH2CH2), 1.60-1.65 (m, 2 H, SCH2CH2), 2.32 (s, 3 H, SC(O)Me), 2.70-
2.90 (m, 16 H, 4×N(CH2)2N), 2.74-2.79 (m, 2 H, (C(O)CH2)), 2.74-2.79 (m, 1 H, 
NCHaCHbCH), 2.85 (t, J= 7.2 Hz, 2 H, SCH2), 3.49 (m, 6 H, 3×C(O)CH2CH3 and 1 H, 
NCHaCHbCH), 3.72 (s, 3 H, C(O)OCH3), 4.19 (m, 6 H, C(O)OCH2CH3), 5.46 (t, J= 5.2 
Hz, 1 H, NCH2CH). HRMS (ESI): m/z: calcd. for C37H68N5O10S [M+H]
+: 774.4681, 
found: 774.4684. 
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Synthesis of (11-mercapto-2-undecanamido-carboxyethyl)-4,7,10-tris-
(carboxymethyl)-1,4,7,10-tetraazacyclododecane - Fully deprotected DO3A-N-(-
mercaptoundecanamido)propionate chelator (L2) 
Compound 8 (0.218 g, 0.28 mmol) was dissolved in a mixture EtOH/H2O (20 
ml, 1:1 (v/v)). The solution was adjusted to pH ~ 10-11 (pH paper) with aqueous NaOH 
(1 M) and left stirring at room temperature overnight. The solution was adjusted to pH ~ 
7 (pH paper) with diluted hydrochloric acid (1M) and was evaporated at reduced 
pressure (temperature < 40 ºC). The residue was adsorbed onto silica and purified by 
flash chromatography (CH2Cl2CH2Cl2/EtOH 1/1EtOHEtOH/H2O 1:1H2O) to 
afford a light yellow foam. The residue was re-dissolved in water and was purified by 
size exclusion chromatography (Sephadex G10). The relevant fractions were pooled 
together and the solvent was removed under reduced pressure to give chelator L2 (0.074 
g, 42 %).1H-NMR (CDCl3, 400 MHz): δ= 1.33 (s (br), 10 H, 5×CH2),1.61 (s (br), 2 H, 
SCH2CH2CH2), 1.63 (s (br), 2 H, (C(O)CH2CH2), 1.72 (s (br), 2 H, SCH2CH2), 2.33 (s 
(br), 2 H, (C(O)CH2), 2.58 (t, J= 6.8 Hz, 2 H, SCH2), 2.80 (s (br), 1 H, NCHaHbCH), 
2.80 (s (br), 1 H, NCHaHbCH), 3.18 (s, 4 H, NCH2CH2NCH2CH), 3.39-3.36 (m, 4 H, 
N(CH2)2N), 3.43 (s, 8 H, 2×N(CH2)2N), 3.76 (s (br), 6 H, 3×NCH2(C(O)OH), 4.52 (s 
(br), 1 H, CH). 13C-NMR (CDCl3, 100.62 MHz): δ= 23.82 (SCH2), 25.13 
(C(O)CH2CH2), 27.73 (SCH2CH2), 28.11, 28.31, 28.39, 28.52, 28.61 (overlapped CH2 
signals), 33.08 (SCH2CH2CH2), 35.84 (C(O)CH2), 38.51 (NCH2CH), 48.79 (2× 
NCH2CH2NCH2CH), 51.20 (CH), 51.62 (2×NCH2CH2NCH2CH), 56.56 (3× 
NCH2(C(O)OH), 56.09 (2×NCH2CH2N), 177.14 (NHC(O)), 177.14 (CHC(O)OH), 
177.30 (3×NCH2C(O)OH). HRMS (ESI): m/z: calcd for C28H51N5NaO9S [M+Na]
+: 
656.3305, found: 656.3300. 
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Preparation of GdL1 and GdL2 complexes for relaxometric measurements 
 
 A solution of GdCl3.6H2O was added drop-wise, under magnetic stirring, to an 
equimolar solution of L1 or L2 (5% excess), while keeping the solution pH around 5.8 
(pH meter) by the addition of diluted NaOH. The solution was left stirring at room 
temperature overnight. Then, the solution was adjusted to pH 7.0 with NaOH (0.1 M) 
and filtered through a 0.2 m syringe filter. The absence of free Gd3+ was confirmed by 
the xylenol orange test. The final concentration of Gd was determined by ICP-OES 
following sample digestion with nitric acid.  
 
Preparation gold nanoparticles functionalized with GdL1 and GdL2 chelates. 
 
An aqueous solution of ligand DO3A-N-(-Lipoamido)propionate (L1) (20.5 
mM, 4.53 ml, 0.091 mmol) was added drop-wise, under magnetic stirring at room 
temperature, to an aqueous solution of HAuCl4 (58.86 mM, 1.54 ml, 0.091 mmol). 
During the initial stages of the addition of L1, the light yellow HAuCl4 solution turned 
dark orange, fading away in color to light yellow with further addition of ligand. To the 
reaction mixture was added, in one aliquot, a freshly prepared aqueous NaBH4 solution 
(522 mM, 0.179 ml, 0.093 mmol). The reaction mixture turned instantaneously dark 
brown and was left stirring at room temperature for 16 hours. The NPs solution was 
adjusted to pH ~ 7 (pH meter) by adding aqueous NaOH (0.1 M) and was filtered 
through a 0.20 m PTFE syringe filter. A small volume of solution (1 ml) was kept for 
further characterization. To remaining NPs solution (~ 5.3 ml) was added slowly a 
solution of GdCl3.6H2O in water (303 M, 0.300 ml, 0.091 mmol) while keeping the 
solution pH around 5.5 (pH meter) by adding aqueous NaOH 0.1 M. The NPs solution 
was left stirring at room temperature for 16 hours and was adjusted to pH ~ 7 with 
aqueous NaOH (1 M solution). The nanoparticles were purified by size exclusion 
chromatography (Sephadex G10, 0.42 m) with elution with water. The entire colored 
broad band eluting from the column was collected without attempting to fractionate the 
sample. The nanoparticles were further purified by extensive dialysis against water 
using a 10 KDa MWCO cellulose membrane. The xylenol orange test indicated the 
absence of free Gd3+ in the gold nanoparticles preparation. 
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The same procedure was followed for the preparation of GdL2@AuNPs starting 
from ligand L2 (20.5 mg/mL, 2 ml, 0.0647 mmol) and HAuCl4 (22 mg/ml, 1 ml, 0.0647 
mmol).  
The Gd and Au content of the NPs preparations ([Gd]= 0.57 mM and 1.30 mM; 
[Au]/[Gd]= 1.40 and 0.87, for GdL1@AuNPs and GdL2@AuNPs, respectively) was 
determined by ICP-OES analysis following sample digestion with aqua regia. 
 
NMRD measurements 
 
The NMD measurements were performed using a Stelar Spinmaster FFC NMR 
relaxometer (0.01-20 MHz) equipped with a VTC90 temperature control unit. At higher 
fields, the 1H relaxivity measurements were performed on Bruker Minispecs mq30 (30 
MHz), mq40 (40 MHz) and mq60 (60 MHz), as well as Bruker Avance spectrometers 
connected to 2.35 T, 4.7 T and 9.4 T superconducting magnets. In each case, the 
temperature was measured by a substitution technique. Variable temperature 
measurements were performed at 25 and 37 ◦C. The NMRD profiles were analysed 
using the Visualiseur/Optimiseur 3.6 program running on a Matlab® 6.5 platform.49  
 
Relaxivity studies of pH dependence and Zn2+ transmetallation 
 
The transmetallation reaction of the GdL1 and GdL2  chelates and of the metal 
chelate-decorated NPs GdL1@AuNps and GdL2@AuNPs against Zn2+, was studied by 
following the time-dependent decrease of the protonic longitudinal relaxation rate, R1, 
(20 MHz, 25 ºC) of phosphate-buffered saline solutions (PBS, pH 7.1, 10 mM), 
containing GdL1, GdL2, GdL1@AuNPs and GdL2@AuNPs ([Gd]= 1.0, 1.13, 0.42, 1.33 
mM, respectively), before and after adding an equimolar amount of ZnCl2, while 
vigorously stirring the solutions. 
The pH dependence of the relaxivity was measured by adjusting the solution pH 
with aqueous diluted NaOH (0.1 M) or diluted hydrochloric acid (0.1 M), using a 
Crison micro TT 2050 pH meter equipped with a Mettler Toledo 422 electrode. A 
Bruker Minispec mq20 relaxometer was used for all measurements (20 MHz, 25 ºC). 
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MRI studies 
 
Preparation of the GdL1@AuNPs and GdL2@AuNPs CA solutions for MRI 
studies. 
 
The GdL1@AuNPs and GdL2@AuNPs CA for the MRI studies were prepared 
following the procedure described above. The final nanoparticles solutions were freeze-
dried and their Gd and Au content (per mg of solid material) were determined by ICP-
OES following digestion with aqua regia.  
 
In vivo MRI studies.  
 
The experimental protocols were approved by the appropriate institutional 
review committees and meet the guidelines of their responsible governmental agency. 
The Magnetic Resonance Imaging (MRI) experiments were all performed on a Bruker 
Pharmascan platform (Bruker Medical GmbH, Ettlingen, Germany) using a 7.0 T (300 
MHz) horizontal-bore superconducting magnet, equipped with a 1H selective 60 mm 
birdcage resonator and a Bruker gradient insert with 90 mm diameter (maximum 
intensity 360 mT/m). Data were acquired using a Hewlett-Packard console running 
Paravision software (Bruker Medical Gmbh, Ettlingen, Germany) under a LINUX 
environment.  
All MRI examinations were carried out on mice (n = 4, ~ 20 g body weight) 
anaesthetized initially by inhalation in an induction box with O2 (1 L/min) containing 3 
% isoflurane, and maintained during the experiment using a face mask allowing free 
breathing and 1-2 % isoflurane on O2. Animals were taped down into a holder, to 
minimize breathing - related motion, and were then placed in a heated probe, which 
maintained the core body temperature at 37 ± 0.5 °C, monitored by a rectal probe. The 
physiological state of the animal was monitored throughout the entire experiment by a 
Biotrig physiological monitor (Bruker Medical GmbH, Ettlingen, Germany), using the 
respiratory rate and body temperature.  
Solutions of GdL1@AuNPs and GdL2@AuNPs 10 mM in [Gd] were prepared 
by dissolving the freeze-dryed NPs in the appropriate volume of PBS buffer. The 
solutions were filtered through a 0.2 m seringe filter before injection. 10 mM 
Gd(DTPA) (Magnevist, Schering, Berlin, Germany) solutions were also prepared. The 
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solutions were injected into the catheterized tail vein as a bolus in 20 s (0.05 and 0.1 
mmol Gd  kg-1 body weight) using an infusion pump (Panlab, Barcelona, Spain).  
Regional contrast agent uptake was assessed using Dynamic Contrast Enhanced 
(DCE) MRI. DCE MRI experiments were performed with series of T1-weighted spin 
echo images sequentially acquired over 1 h, before and following the injection of the 
contrast agent 10 min after the beginning of the study. The acquisition parameters were: 
TR = 310 ms, TE = 10.58 ms, number of averages = 2, ten coronal slices, slice thickness 
= 2 mm, FOV = 5.0 x 5.0 cm, matrix = 256 x 256, 30 repetitions with a total acquision 
time of 119 s.  
 
MRI data analysis.  
 
Data were analyzed with the public domain software Image J 
(http://rsbweb.nih.gov/ij/). With the aim of comparing the pharmacokinetics obtained 
from different animals, the data were normalized by calculating the percentage of 
relative, rather than absolute, enhancement: 
   100
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0
0 


I
II
RE  
where I is the signal intensity at any given time after CA injection and I0 is the intensity 
before injection. Pharmacokinetic behaviour was analyzed by calculating the average 
enhancements within the different regions of interest (ROIs) placed on each one of the 
following regions: liver, kidney medulla, kidney cortex and muscle. 
 
Biodistribution of radiolabeled nanoparticles 
 
Preparation of [153Sm]L1@AuNPs chelates for the biodistribution studies 
 
In these studies 153Sm3+ was used as a radioactive surrogate of Gd3+.  [153SmCl3] 
(1 mCi) was added to a solution of L1@AuNPs (5 mg freeze-dried NPs) in sodium 
acetate buffer (400 μL, 0.4 M, pH 5). The solution was stirred at 80 ºC for 5 hours. 
After that, cold SmCl3 was added to each solution in order to obtain an equimolar 
Sm3+:chelator ratio. The final solution was heated at 80 ºC for 2 hours and left overnight 
at room temperature. The radiolabeled nanoparticles were purified by size exclusion 
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chromatography using a Sephadex G-10 column eluted with 0.4 M acetate buffer. The 
whole colored broad band eluting from the column was collected and concentrated by 
centrifugal filtration (Centricon 10 kDa MWCO membrane, Millipore).   
 
Biodistribution studies 
 
Groups of four animals (Wistar rat males weighting ca 200 g) were 
anaesthetized with Ketamine (50.0 mg/mL)/chloropromazine (2.5%) (10:3) and injected 
in the femoral vein with ca 100 Ci of  [153Sm]L1@AuNPs and sacrificed 2 and 24 
hours later. The major organs were excised, weighed and the tissue radioactivity was 
measured in a  well-counter. Blood samples were obtained at appropriate periods of 
time, weighted and radioactivity counted.  
National regulations for the care and use of laboratory animals were strictly followed in 
this study. 
 
Semiempirical calculations, molecular modelling and NPs size estimates  
 
All calculations were performed with Mopac code50 using the semiempirical 
model Hamiltonian PM651 and COSMO52 implicit water solvent model (ε= 74.8 with 
Gd and Au tesserae radius taken as 0.2 nm). The length of the chelates was estimated 
from various chelate conformers averaged over several S…O and S…H top bottom 
distances within conformers (Figure SI5); ascribing an error of 0.1 nm to the estimates 
seems reasonable for this methodology. The average AuNPs diameter is estimated from 
the diameter exclusion of the left and right chelates (Table SI2).   
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Figure SI1. Temperature dependence of the water proton longitudinal relaxation rate for GdL1 
(20 MHz, 1.0 mM pH 7.0 (■)) and for GdL2 (20 MHz, 1.13 mM, pH 7.1(♦)) 
 
 
Figura SI2. Size distribution (%Volume) for GdL2 (5.67 mM, pH 7.1, 25 ºC).  
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Figure SI3. pH dependence of the water proton longitudinal relaxation rate for GdL1 (20 MHz, 
1.0 mM, 25 ºC (■)) and for GdL2 (20 MHz, 1.13 mM, 25 ºC (♦)). 
 
 
Figure SI4. Time evolution of the relative water proton relaxation rate R1p(t)/R1p(0) (20 MHz, 
37 ºC) for a solution of GdL2 (1.13 mM in PBS 2.5 mM, pH 7.1) (♦) and following addition of 
ZnCl2 0.75 mM (■). 
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Figure SI5. Typical chelate length estimates from several Au…O and Au…H top-bottom 
distances measured over the optimized conformations of (A) GdL1, (B) GdL2 and (C) GdL3 
obtained from PM6 semi-empirical calculations. Structures visualized with Jmol code [4]. 
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Figure SI6. UV-Vis spectrum of GdL1@AuNPs. 
 
 
 
 
 
 
 
 
Figure SI7. UV-Vis spectrum of GdL2@NPs. 
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Figure SI8. Zeta potential distribution, expressed as total counts, for GdL1@AuNPs (green line) 
and GdL2@AuNPs (red line). 
 
Table SI1. Zeta potencial for the GdL1@AuNPs and GdL2@AuNPs. 
AuNPs  Zeta potential (mV) 
GdL1@AuNPs -6.3 
GdL2@AuNPs -13.7 
 
 
 
Figure SI9. Concentration dependence of the paramagnetic water proton relaxation rate R1p  
(R1p = R1obs-R1d) for GdL1@NPs (■) and GdL2 @NPs (♦) (20 MHz, 25 ºC, pH 7.1). 
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Figure SI10. pH dependence of the paramagnetic water proton relaxation rate for 
GdL1@AuNPs (20 MHz, 25 ºC, 0.53 mM, (■)) and for GdL2@AuNPs (20 MHz, 25 ºC, 1.30 
mM (♦)). 
 
 
 
Figure SI11. Time evolution of the relative water proton paramagnetic relaxation rate 
R1p(t)/R1p(0) (20 MHz, 25 ºC) for a solution of GdL1@NPs (0.53 mM in PBS 2.5 mM, pH 7.1) 
(♦) and following addition of  0.75 mM ZnCl2 (●).  
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Figure SI12. Time evolution of the relative water proton paramagnetic relaxation rate 
R1p(t)/R1p(0) (20 MHz, 25 ºC) for a solution of GdL2@AuNPs (1.30 mM in PBS 10 mM, pH 
7.1) (■) and following addition of 0.75 mM ZnCl2 (♦).  
 
Table SI2. Characterization of GdL1@AuNPs and GdL2@AuNPs 
 GdL1@AuNPs
a GdL2@AuPs
a GdL3@AuNPs
b 
[Gd] (mM) ([Au]/[Gd])c 0.57 (1.4) 1.30 (0.87) 1.24 (3.0) 
HD (nm)d 4.8 5.9 3.9 
Chelate length (nm)e 1.9 2.5 1.6f 
Au core diam (nm)g 1.0 0.9 0.7f 
Zeta potential (mV) -6.3 -13.7 -12.3 
NAu core
h 31 23 11f 
NChel/NP
i 22j  26j 4f 
r1 (mM -1 s-1; 20 MHz, 25 ºC) 27
 38 28 
r1vol (mM -1 s-1 nm-3; 20 MHz, 25 ºC)
k
 - - 13 
aThe synthesis and characterization of L1, L2, GdL1, GdL2 and GdL1@AuNPs and GdL2@AuNPs is 
described in this work. 
bThe synthesis and characterization of L3 and GdL3@AuNPs was described before [1]. 
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cThe concentration of Gd and Au on the NPs solutions was determined by ICP-OES following digestion 
of the NPs with aqua regia.  
dThe hydrodynamic diameter (HD, nm) of the NPs was measured by DLS. 
eThe length of GdL1 and GdL2 was estimated by PM6 semi-empirical calculations for the most provable 
distended conformations (Figure SI5).  
fThe length of GdL3 was estimated by PM6 semi-empirical calculations for the most provable distended 
conformation, affording a revised value of 1.6 nm comparing to previous estimates of 1 nm [1].  
gThe diameter of the gold core was estimated by taking into account the hydrodynamic diameter of the 
NPs measured by DLS, and the thickness of the chelate monolayer: Aucore = HD-2xChellenght  
hThe number of Au atoms in the NPs core (NAu= 30.9D3) was calculated from the diameter of the metal 
core (D, nm) [2].  
i The number of immobilized complexes was calculated from the number of Au atoms in the core and the 
ratio Au/Gd obtained by ICP-OES. 
jA low ratio Au/Gd has obtained by ICP-OES for GdL1@AuNPs (1.40) and especially for GdL2@AuNPs 
(0.87) comparing to GdL3@AuNPs (3.0) [1]. The number of immobilized chelates (22 and 26 chelates for 
GdL1@AuNPs and GdL2@AuNPs, respectively), calculated from the number of Au atoms in the metal 
core and the ratio Au/Gd), suggests the formation of a loosely bound second chelate layer around the NPs.  
This possibility deserves future investigation.   
  kThe volumetric density of relaxivity was calculated using the relaxivity per NP and the HD diameter of 
the naoparticles: r1vol= (Nchel  x r1)/4/3π(HD/2)3  [3] 
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